JM 3100 Clinical Trials

All Categories Medications / Interventions » Jj-Kk » JM 3100

Collection of Transplant Stem Cells for Plasma Cell Myeloma

Condition: Plasma Cell Myeloma
Interventions: Drug: Filgrastim; Drug: Plerixafor; Procedure: Apheresis
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012
Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma

Conditions: Hodgkin Disease; Hodgkin Lymphoma
Interventions: Drug: Filgrastim; Drug: Plerixafor; Drug: Yttrium-Daclizumab (CHX-A Daclizumab); Drug: Carmustine; Drug: Etoposide; Drug: Cytarabine; Drug: Melphalan; Drug: Ca(2+)-DTPA
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011
Stem Cell Transplantation for Patients With Multiple Myeloma

Condition: Myeloma
Interventions: Drug: G-CSF; Drug: Plerixafor; Procedure: Apheresis; Drug: Melphalan; Procedure: Stem cell re-infusion; Drug: Basiliximab; Device: CliniMACS CD25 microbeads and cell sorter
Sponsors: University of Chicago; University of Chicago
Recruiting - verified January 2012
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncutaneous Extranodal Lymphoma; Peripheral T-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Hairy Cell Leukemia; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Testicular Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: plerixafor; Biological: filgrastim; Drug: etoposide; Procedure: leukapheresis
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)

Condition: Leukemia, Lymphocytic, Chronic, B-Cell
Intervention: Drug: Lenalidomide + Plerixafor (+ Rituximab)
Sponsors: Duke University; Duke University; Celgene Corporation; Genzyme
Recruiting - verified January 2012
Endogenous Progenitors Cell Therapy for Diabetic Foot Ulcers

Condition: Diabetic Ulcer
Intervention: Drug: AMD3100 injection + rhPDGF-BB topical
Sponsors: New York University School of Medicine; New York University School of Medicine; National Institutes of Health (NIH); Genzyme
Not yet recruiting - verified May 2011
Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation

Conditions: Non-Hodgkin's Lymphoma; Multiple Myeloma
Interventions: Drug: Plerixafor; Drug: Filgrastim
Sponsors: University of Florida; University of Florida
Recruiting - verified March 2012
Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)

Condition: Acute Myeloid Leukemia
Interventions: Drug: plerixafor; Drug: decitabine
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University; Genzyme
Recruiting - verified June 2011
Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma

Conditions: High Grade Glioma: Glioblastoma (GBM); High Grade Glioma: Gliosarcoma; Anaplastic Astrocytoma (AA); Anaplastic Oligodendroglioma (AO); Mixed Anaplastic Oligoastrocytoma (AOA)
Interventions: Drug: Plerixafor; Drug: Plerixafor; Drug: Bevacizumab; Drug: Plerixafor; Procedure: Surgery
Sponsors: Dana-Farber Cancer Institute; Patrick Y. Wen, MD; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital; Genzyme
Recruiting - verified February 2012
Gene Therapy for Fanconi Anemia

Condition: Fanconi Anemia
Interventions: Biological: filgrastim; Drug: plerixafor; Procedure: leukapheresis; Biological: genetically engineered lymphocyte therapy; Other: laboratory biomarker analysis; Genetic: polymerase chain reaction
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012
Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma

Conditions: Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma
Interventions: Procedure: peripheral blood stem cell transplantation (PBSCT); Biological: filgrastim; Genetic: polymerase chain reaction; Biological: rituximab; Biological: genetically engineered lymphocyte therapy; Other: laboratory biomarker analysis; Drug: plerixafor; Procedure: autologous hematopoietic stem cell transplantation
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients

Conditions: Relapsed/Refractory AML; Relapsed/Refractory ALL; Secondary AML/MDS; Acute Leukemia of Ambiguous Lineage; AML; ALL
Intervention: Drug: Plerixafor Dose Escalation
Sponsors: Emory University; Emory University; Children's Healthcare of Atlanta; Pediatric Oncology Experimental Therapeutics Investigation Consortium
Recruiting - verified January 2012
Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide

Condition: Refractory Multiple Myeloma
Interventions: Drug: plerixafor; Biological: filgrastim
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant

Condition: Failure of Bone Marrow Graft
Intervention: Drug: Plerixafor
Sponsors: Duke University; Duke University; Genzyme
Recruiting - verified February 2012
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg

Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: G-CSF (filgrastim) plus Plerixafor Injection; Drug: G-CSF (filgrastim) plus Plerixafor Injection
Sponsors: Genzyme; Genzyme
Recruiting - verified April 2012
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors

Conditions: Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Lymphoma, Non-Hodgkin; Hodgkin Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Multiple Myeloma
Intervention: Drug: Sargramostim and plerixafor
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified November 2011
Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)

Condition: Acute Myelogenous Leukemia
Interventions: Drug: Plerixafor; Drug: Clofarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genzyme
Recruiting - verified April 2012
Collection of Peripheral Blood Stem Cells Using G-CSF and Plerixafor in Normal Volunteers

Condition: Normal Volunteer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011
Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells

Conditions: Adult Non-Hodgkin Lymphoma; Adult Grade III Lymphomatoid Granulomatosis; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Primary Central Nervous System Non-Hodgkin Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Small Lymphocytic Lymphoma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Biological: filgrastim; Drug: plerixafor; Biological: rituximab; Drug: ifosfamide; Drug: carboplatin; Drug: etoposide; Procedure: leukapheresis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection

Conditions: Myeloma; Lymphoma
Intervention: Drug: Plerixafor
Sponsors: Emory University; Emory University; Genzyme
Recruiting - verified March 2012
Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma

Conditions: Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: plerixafor; Biological: filgrastim; Drug: cyclophosphamide; Procedure: autologous hematopoietic stem cell transplantation; Other: laboratory biomarker analysis
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified January 2012
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS)

Condition: Myelodysplastic Syndromes
Interventions: Drug: G-CSF, Plerixafor and Azacitidine; Drug: G-CSF, Plerixafor and Azacitidine; Drug: G-CSF, Plerixafor and Azacitidine
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011
A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation

Conditions: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Myelodysplastic Syndrome; Non-Hodgkin's Lymphoma
Intervention: Drug: Plerixafor
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; Genzyme
Recruiting - verified May 2012
Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection

Conditions: Multiple Myeloma; Non-Hodgkins Lymphoma
Intervention: Drug: Plerixafor
Sponsors: Shi, Patricia, M.D.; Shi, Patricia, M.D.; Genzyme
Recruiting - verified September 2011
Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant

Condition: Stem Cell Transplant Patients
Intervention: Drug: G-CSF +/- AMD3100
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified September 2011
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition: Acute Myeloid Leukemia
Intervention: Drug: Plerixafor
Sponsors: Genzyme; Genzyme
Recruiting - verified January 2012
A Phase I Study of Mozobil(Trademark) in the Treatment of Patients With WHIMS

Conditions: WHIMS; Neutrophil Disorder; Myelokathexis; Hypogammaglobulinemia
Intervention: Drug: Mozobil (TM)
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012
Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations

Conditions: Acute Myelogenous Leukemia; Leukemia
Interventions: Drug: G-CSF; Drug: Plerixafor; Drug: Sorafenib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bayer; Genzyme; Onyx Pharmaceuticals
Recruiting - verified February 2012
Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Plerixafor (AMD3100); Drug: bortezomib
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Genzyme
Recruiting - verified May 2012
Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia

Condition: Leukemia, Myeloid, Acute
Interventions: Drug: G-CSF; Drug: Plerixafor; Drug: Mitoxantrone; Drug: Etoposide; Drug: Cytarabine
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011
Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma

Conditions: Lymphoma, Non-Hodgkin; Hodgkin Disease
Interventions: Drug: AMD3100; Drug: G-CSF; Procedure: Apheresis
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011
An Evaluation of Safety and Efficacy of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers

Condition: Stem Cell Mobilization
Intervention: Drug: AMD3100
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2012
G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers

Condition: Healthy
Intervention: Drug: AMD3100
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified November 2011
AMD3100 to Mobilize Stem Cells for Donation

Conditions: Healthy; Blood Component Removal
Intervention: Drug: AMD3100
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified August 2011